Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.

Adenocarcinoma / genetics Adult Aged Biomarkers, Tumor / analysis Colorectal Neoplasms / genetics Cyclooxygenase 2 / biosynthesis Databases, Factual Female Humans Male Middle Aged Mutation Prognosis Proto-Oncogene Proteins B-raf / genetics Retrospective Studies Up-Regulation
Adenocarcinoma Clinical outcome Colorectal neoplasm Immunity Inflammation Molecular pathological epidemiology PTGS Precision medicine Prostaglandin RAF

Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
04 2019
Historique:
received: 15 11 2018
revised: 09 01 2019
accepted: 20 01 2019
pubmed: 4 3 2019
medline: 27 5 2020
entrez: 4 3 2019
Statut: ppublish

Résumé

Prostaglandin-endoperoxide synthase 2 (PTGS2, cyclooxygenase-2, COX-2)-prostaglandin E Using 1708 patients, including 1200 stage I-IV colorectal carcinoma cases in the Nurses' Health Study (NHS) and the Health Professionals Follow-up Study (HPFS) and 508 stage III colon cancer cases in a National Cancer Institute-sponsored randomised controlled trial of adjuvant therapy (CALGB/Alliance 89803), we evaluated tumour PTGS2 (COX-2) expression status using immunohistochemistry. We examined the prognostic association of PTGS2 (COX-2) expression in strata of BRAF mutation status by multivariable Cox proportional hazards regression models to adjust for potential confounders, including disease stage, tumour differentiation, microsatellite instability status and KRAS and PIK3CA mutations. In NHS and HPFS, the association of PTGS2 (COX-2) expression with colorectal cancer-specific survival differed by BRAF mutation status (P The association of tumour PTGS2 (COX-2) expression with colorectal cancer mortality is stronger in BRAF-mutated tumours than in BRAF-wild-type tumours, supporting interactive roles of PTGS2 (COX-2) expression and BRAF mutation statuses in prognostication of patients with colorectal cancer; ClinicalTrials.gov Identifier, NCT00003835.

Sections du résumé

BACKGROUND
Prostaglandin-endoperoxide synthase 2 (PTGS2, cyclooxygenase-2, COX-2)-prostaglandin E
METHODS
Using 1708 patients, including 1200 stage I-IV colorectal carcinoma cases in the Nurses' Health Study (NHS) and the Health Professionals Follow-up Study (HPFS) and 508 stage III colon cancer cases in a National Cancer Institute-sponsored randomised controlled trial of adjuvant therapy (CALGB/Alliance 89803), we evaluated tumour PTGS2 (COX-2) expression status using immunohistochemistry. We examined the prognostic association of PTGS2 (COX-2) expression in strata of BRAF mutation status by multivariable Cox proportional hazards regression models to adjust for potential confounders, including disease stage, tumour differentiation, microsatellite instability status and KRAS and PIK3CA mutations.
RESULTS
In NHS and HPFS, the association of PTGS2 (COX-2) expression with colorectal cancer-specific survival differed by BRAF mutation status (P
CONCLUSIONS
The association of tumour PTGS2 (COX-2) expression with colorectal cancer mortality is stronger in BRAF-mutated tumours than in BRAF-wild-type tumours, supporting interactive roles of PTGS2 (COX-2) expression and BRAF mutation statuses in prognostication of patients with colorectal cancer; ClinicalTrials.gov Identifier, NCT00003835.

Identifiants

DOI: 10.1016/j.ejca.2019.01.022 PMID: 30826660 PMC: PMC6436990
pubmed: 30826660
pii: S0959-8049(19)30043-7
doi: 10.1016/j.ejca.2019.01.022
pmc: PMC6436990
mid: NIHMS1009275
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Cyclooxygenase 2 EC 1.14.99.1
PTGS2 protein, human EC 1.14.99.1
BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1

Banques de données

ClinicalTrials.gov
['NCT00003835']

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

82-93

Subventions

Organisme : NCI NIH HHS
ID : R01 CA118553
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA137178
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA205406
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180882
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180867
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA127003
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA190673
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233290
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197735
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA055075
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA151993
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167552
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180821
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIDDK NIH HHS
ID : K24 DK098311
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA169141
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233180
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA196171
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA188126
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA167552
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

Clin Colorectal Cancer. 2017 Sep;16(3):165-172
pubmed: 27810226
Cell Death Dis. 2014 Dec 11;5:e1568
pubmed: 25501829
Eur J Cancer. 2017 Sep;82:16-24
pubmed: 28651158
Gastroenterology. 2015 Dec;149(7):1884-1895.e4
pubmed: 26261008
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Trends Mol Med. 2016 Jan;22(1):1-3
pubmed: 26711015
Nat Rev Cancer. 2014 Nov;14(11):736-46
pubmed: 25342631
Neoplasia. 2018 Jul;20(7):721-733
pubmed: 29859426
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Oncogene. 2014 Feb 27;33(9):1158-66
pubmed: 23455323
Oncoimmunology. 2015 Apr 1;4(7):e1016700
pubmed: 26140242
JAMA. 2013 Jun 26;309(24):2563-71
pubmed: 23800934
Gut. 2009 Jan;58(1):90-6
pubmed: 18832519
PLoS One. 2017 Jan 26;12(1):e0170775
pubmed: 28125730
Transl Res. 2018 Jun;196:42-61
pubmed: 29421522
Cancer Discov. 2018 Feb;8(2):164-173
pubmed: 29196463
Ann Oncol. 2017 Mar 1;28(3):562-568
pubmed: 27993800
J Clin Oncol. 2017 Jun 1;35(16):1836-1844
pubmed: 28406723
N Engl J Med. 2007 May 24;356(21):2131-42
pubmed: 17522398
Eur J Cancer. 2018 Sep;100:35-45
pubmed: 29936065
Oncoimmunology. 2016 Jan 04;5(5):e1123370
pubmed: 27467936
Gut. 2012 Jun;61(6):847-54
pubmed: 22427238
Clin Transl Gastroenterol. 2017 Apr 27;8(4):e91
pubmed: 28448072
Front Immunol. 2017 Mar 08;8:248
pubmed: 28337200
J Clin Oncol. 2017 Aug 20;35(24):2806-2813
pubmed: 28617623
Clin Cancer Res. 2012 Feb 1;18(3):890-900
pubmed: 22147942
Front Immunol. 2017 Feb 02;8:71
pubmed: 28210259
Gut. 2018 Jun;67(6):1168-1180
pubmed: 29437869
Lancet. 2018 May 26;391(10135):2084-2086
pubmed: 29754776
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1117-1122
pubmed: 28096371
Eur J Cancer. 2018 Nov;103:98-107
pubmed: 30219720
Mol Cell. 2010 Aug 27;39(4):493-506
pubmed: 20797623
N Engl J Med. 2012 Oct 25;367(17):1596-606
pubmed: 23094721
Gut. 2016 Sep;65(9):1470-81
pubmed: 25994220
Clin Gastroenterol Hepatol. 2019 Feb;17(3):455-462.e6
pubmed: 29660527
Nat Rev Cancer. 2017 Feb;17(2):79-92
pubmed: 28050011
J Natl Cancer Inst. 2016 Dec 31;109(5):
pubmed: 28040692
Ann Oncol. 2017 Nov 1;28(11):2648-2657
pubmed: 29045527
Cell. 2015 Sep 10;162(6):1257-70
pubmed: 26343581
Nat Hum Behav. 2018 Jan;2(1):6-10
pubmed: 30980045

Auteurs

Keisuke Kosumi (K)

Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.

Tsuyoshi Hamada (T)

Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

Sui Zhang (S)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

Li Liu (L)

Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology and Biostatistics, and the Ministry of Education Key Lab of Environment and Health, School of Public Health, Huazhong University of Science and Technology, Wuhan, PR China.

Annacarolina da Silva (A)

Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

Hideo Koh (H)

Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Department of Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.

Tyler S Twombly (TS)

Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

Kosuke Mima (K)

Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.

Teppei Morikawa (T)

Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Mingyang Song (M)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.

Jonathan A Nowak (JA)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Reiko Nishihara (R)

Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Leonard B Saltz (LB)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Donna Niedzwiecki (D)

Alliance Statistics and Data Center and Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.

Fang-Shu Ou (FS)

Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.

Tyler Zemla (T)

Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.

Robert J Mayer (RJ)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

Hideo Baba (H)

Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.

Kimmie Ng (K)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

Marios Giannakis (M)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Xuehong Zhang (X)

Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Kana Wu (K)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Edward L Giovannucci (EL)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Andrew T Chan (AT)

Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Charles S Fuchs (CS)

Yale Cancer Center, New Haven, CT, USA; Department of Medicine, Yale School of Medicine, New Haven, CT, USA; Smilow Cancer Hospital, New Haven, CT, USA.

Jeffrey A Meyerhardt (JA)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

Shuji Ogino (S)

Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA. Electronic address: shuji_ogino@dfci.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Adénocarcinome › Prognostic association of PTGS2 (COX-2)...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Prognostic association of PTGS2 (COX-2)...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Prognostic association of PTGS2 (COX-2)...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Prognostic association of PTGS2 (COX-2)...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies du rectum › Tumeurs colorectales › Prognostic association of PTGS2 (COX-2)...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Complexes multienzymatiques › Cyclooxygenase 2 › Prognostic association of PTGS2 (COX-2)...
questionsmedicales.fr › Sciences de l'information › Mémorisation et recherche des informations › Bases de données comme sujet › Bases de données factuelles › Prognostic association of PTGS2 (COX-2)...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Prognostic association of PTGS2 (COX-2)...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Prognostic association of PTGS2 (COX-2)...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Prognostic association of PTGS2 (COX-2)...
questionsmedicales.fr › Diagnostic › Pronostic › Prognostic association of PTGS2 (COX-2)...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Kinases raf › Protéines proto-oncogènes B-raf › Prognostic association of PTGS2 (COX-2)...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Prognostic association of PTGS2 (COX-2)...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Régulation positive › Prognostic association of PTGS2 (COX-2)...